Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

"RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull" was originally created and published by Clinical ...

Repeat administration of MDNA11 at the target doses continues ... Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W MDNA11 and 400 mg Q6W KEYTRUDA.

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

For this use, Keytruda received accelerated approval from the Food and Drug Administration (FDA). Accelerated approval is based on information from early clinical studies. The FDA’s decision for ...

The company also has a solid dividend record. Its payouts have increased by 71% in the past decade, and it currently offers a ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Keytruda has previously been approved by the Food and Drug Administration as monotherapy and in combination with other therapies for some patients with metastatic or unresectable, recurrent head and ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...